Celgene ( Celgene )


Celgene's picture

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

Celgene press release, blog etc

03/06/2018 - 04:30 Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
03/05/2018 - 07:25 Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.
02/27/2018 - 14:55 Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
02/21/2018 - 05:50 Celgene Receives Antitrust Clearance for Juno Acquisition
02/17/2018 - 05:41 OTEZLA (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behet's Disease with Oral Ulcers
02/15/2018 - 10:47 OTEZLA (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis
02/15/2018 - 10:01 Celgene Corporation Elects John Weiland to Its Board of Directors
02/14/2018 - 17:10 A Closer Look at Mucosal Healing in Ulcerative Colitis
02/14/2018 - 06:46 Celgene Announces Additional $5 Billion Share Repurchase Authorization
02/12/2018 - 12:09 Celgene unveils state-of-the-art cellular immunotherapy manufacturing facility
02/09/2018 - 06:53 Celgene Prices $4.5 Billion of Senior Unsecured Notes
02/06/2018 - 05:08 Celgene Corporation Announces Positive Results from the Pivotal Phase III OPTIMISMM' Study of POMALYST/IMNOVID for the Treatment of Relapsed or Refractory Multiple Myeloma
02/02/2018 - 04:22 Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.
01/29/2018 - 10:11 Celgene Announces Retirement of Executive Chairman Bob Hugin and Appointment of CEO Mark Alles as Chairman of the Board of Directors
01/22/2018 - 13:47 Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy
01/19/2018 - 13:48 Investigational Data Presented at ASCO GI Evaluate ABRAXANE Regimen for Patients with Locally Advanced Pancreatic Cancer
01/10/2018 - 12:14 Relapse Rates: A Benchmark for Measuring MS Treatment Efficacy
01/07/2018 - 12:02 Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies